Study of side effect reduction of anticancer agents by regulation of exogenous gene expression

点击翻译按钮获取中文摘要

For the purpose of regulation of transgene expression after gene introduction in gene therapy, the levels of CMV-promoter-driven transgene expression was analyzed when transgene introduced cells was exposed by anticancer agents. The levels of CMV-promoter-driven transgene expression were increased by doxorubicin (Dox) exposure. The induction of CMV-promoter-driven transgene expression by Dox was decreased by co-treatment of edaravone. We also found that phosphorylation pathway of AP-1 having CMV-promoter binding ability was activated by Dox.